Aminopeptidase N - Pipeline Review, H1 2018

Aminopeptidase N (Myeloid Plasma Membrane Glycoprotein CD13 or Alanyl Aminopeptidase or Aminopeptidase M or Microsomal Aminopeptidase or gp150 or CD13 or ANPEP or EC 3.4.11.2) - Pipeline Review, H1 2018

Summary

According to the recently published report Aminopeptidase N - Pipeline Review, H1 2018; Aminopeptidase N (Myeloid Plasma Membrane Glycoprotein CD13 or Alanyl Aminopeptidase or Aminopeptidase M or Microsomal Aminopeptidase or gp150 or CD13 or ANPEP or EC 3.4.11.2) pipeline Target constitutes close to 8 molecules. Out of which approximately 5 molecules are developed by companies and remaining by the universities/institutes.

Aminopeptidase N (Myeloid Plasma Membrane Glycoprotein CD13 or Alanyl Aminopeptidase or Aminopeptidase M or Microsomal Aminopeptidase or gp150 or CD13 or ANPEP or EC 3.4.11.2) - Aminopeptidase N (AP-N) or membrane alanyl aminopeptidase or alanyl aminopeptidase (AAP) is an enzyme encoded by the ANPEP gene. It plays a role in the final digestion of peptides generated from hydrolysis of proteins by gastric and pancreatic proteases. It also involved in the processing of various peptides including peptide hormones, such as angiotensin III and IV, neuropeptides, and chemokines. It has a role in angiogenesis and promotes cholesterol crystallization.

The report Aminopeptidase N - Pipeline Review, H1 2018 outlays comprehensive information on the Aminopeptidase N (Myeloid Plasma Membrane Glycoprotein CD13 or Alanyl Aminopeptidase or Aminopeptidase M or Microsomal Aminopeptidase or gp150 or CD13 or ANPEP or EC 3.4.11.2) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type; that are being developed by Companies / Universities.

It also reviews key players involved in Aminopeptidase N (Myeloid Plasma Membrane Glycoprotein CD13 or Alanyl Aminopeptidase or Aminopeptidase M or Microsomal Aminopeptidase or gp150 or CD13 or ANPEP or EC 3.4.11.2) targeted therapeutics development with respective active and dormant or discontinued projects. Currently, The molecules developed by companies in Pre-Registration, Phase II, Phase I and Preclinical stages are 1, 1, 2 and 1 respectively.

Similarly, the universities portfolio in Phase I, Preclinical and Discovery stages comprises 1, 1 and 1 molecules, respectively. Report covers products from therapy areas Oncology, Central Nervous System, Hematological Disorders and Ophthalmology which include indications Malignant Pleural Mesothelioma, Acute Pain, Cancer Pain, Keratoconjunctivitis sicca (Dry Eye), Lung Cancer, Lymphedema, Lymphoma, Melanoma, Migraine, Neuropathic Pain, Ocular Pain, Pain, Post-Operative Pain, Solid Tumor and Traumatic Pain.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

- The report provides a snapshot of the global therapeutic landscape for Aminopeptidase N (Myeloid Plasma Membrane Glycoprotein CD13 or Alanyl Aminopeptidase or Aminopeptidase M or Microsomal Aminopeptidase or gp150 or CD13 or ANPEP or EC 3.4.11.2)
- The report reviews Aminopeptidase N (Myeloid Plasma Membrane Glycoprotein CD13 or Alanyl Aminopeptidase or Aminopeptidase M or Microsomal Aminopeptidase or gp150 or CD13 or ANPEP or EC 3.4.11.2) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
- The report reviews key players involved in Aminopeptidase N (Myeloid Plasma Membrane Glycoprotein CD13 or Alanyl Aminopeptidase or Aminopeptidase M or Microsomal Aminopeptidase or gp150 or CD13 or ANPEP or EC 3.4.11.2) targeted therapeutics and enlists all their major and minor projects
- The report assesses Aminopeptidase N (Myeloid Plasma Membrane Glycoprotein CD13 or Alanyl Aminopeptidase or Aminopeptidase M or Microsomal Aminopeptidase or gp150 or CD13 or ANPEP or EC 3.4.11.2) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type
- The report summarizes all the dormant and discontinued pipeline projects
- The report reviews latest news and deals related to Aminopeptidase N (Myeloid Plasma Membrane Glycoprotein CD13 or Alanyl Aminopeptidase or Aminopeptidase M or Microsomal Aminopeptidase or gp150 or CD13 or ANPEP or EC 3.4.11.2) targeted therapeutics

Reasons to buy

- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Identify and understand the targeted therapy areas and indications for Aminopeptidase N (Myeloid Plasma Membrane Glycoprotein CD13 or Alanyl Aminopeptidase or Aminopeptidase M or Microsomal Aminopeptidase or gp150 or CD13 or ANPEP or EC 3.4.11.2)
- Identify the use of drugs for target identification and drug repurposing
- Identify potential new clients or partners in the target demographic
- Develop strategic initiatives by understanding the focus areas of leading companies
- Plan mergers and acquisitions effectively by identifying key players and its most promising pipeline therapeutics
- Devise corrective measures for pipeline projects by understanding Aminopeptidase N (Myeloid Plasma Membrane Glycoprotein CD13 or Alanyl Aminopeptidase or Aminopeptidase M or Microsomal Aminopeptidase or gp150 or CD13 or ANPEP or EC 3.4.11.2) development landscape
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and Scope


List of Tables 5
List of Figures 5
Introduction 6
Global Markets Direct Report Coverage 6
Aminopeptidase N (Myeloid Plasma Membrane Glycoprotein CD13 or Alanyl Aminopeptidase or Aminopeptidase M or Microsomal Aminopeptidase or gp150 or CD13 or ANPEP or EC 3.4.11.2) - Overview 7
Aminopeptidase N (Myeloid Plasma Membrane Glycoprotein CD13 or Alanyl Aminopeptidase or Aminopeptidase M or Microsomal Aminopeptidase or gp150 or CD13 or ANPEP or EC 3.4.11.2) - Therapeutics Development 8
Products under Development by Stage of Development 8
Products under Development by Therapy Area 9
Products under Development by Indication 10
Products under Development by Companies 12
Products under Development by Universities/Institutes 14
Aminopeptidase N (Myeloid Plasma Membrane Glycoprotein CD13 or Alanyl Aminopeptidase or Aminopeptidase M or Microsomal Aminopeptidase or gp150 or CD13 or ANPEP or EC 3.4.11.2) - Therapeutics Assessment 16
Assessment by Mechanism of Action 16
Assessment by Route of Administration 17
Assessment by Molecule Type 19
Aminopeptidase N (Myeloid Plasma Membrane Glycoprotein CD13 or Alanyl Aminopeptidase or Aminopeptidase M or Microsomal Aminopeptidase or gp150 or CD13 or ANPEP or EC 3.4.11.2) - Companies Involved in Therapeutics Development 21
MolMed SpA 21
Nippon Kayaku Co Ltd 21
Pharmaleads SA 22
Aminopeptidase N (Myeloid Plasma Membrane Glycoprotein CD13 or Alanyl Aminopeptidase or Aminopeptidase M or Microsomal Aminopeptidase or gp150 or CD13 or ANPEP or EC 3.4.11.2) - Drug Profiles 23
MT-954 - Drug Profile 23
Product Description 23
Mechanism Of Action 23
R&D Progress 23
NGR-hTNF - Drug Profile 24
Product Description 24
Mechanism Of Action 24
R&D Progress 24
PL-265 - Drug Profile 30
Product Description 30
Mechanism Of Action 30
R&D Progress 30
PL-37 - Drug Profile 32
Product Description 32
Mechanism Of Action 32
R&D Progress 32
Recombinant Protein to Inhibit CD13 for Lymphoma and Solid Tumor - Drug Profile 34
Product Description 34
Mechanism Of Action 34
R&D Progress 34
Small Molecules to Inhibit ANPEP for Oncology - Drug Profile 35
Product Description 35
Mechanism Of Action 35
R&D Progress 35
STR-324 - Drug Profile 36
Product Description 36
Mechanism Of Action 36
R&D Progress 36
ubenimex - Drug Profile 38
Product Description 38
Mechanism Of Action 38
R&D Progress 38
Aminopeptidase N (Myeloid Plasma Membrane Glycoprotein CD13 or Alanyl Aminopeptidase or Aminopeptidase M or Microsomal Aminopeptidase or gp150 or CD13 or ANPEP or EC 3.4.11.2) - Dormant Products 41
Aminopeptidase N (Myeloid Plasma Membrane Glycoprotein CD13 or Alanyl Aminopeptidase or Aminopeptidase M or Microsomal Aminopeptidase or gp150 or CD13 or ANPEP or EC 3.4.11.2) - Discontinued Products 43
Aminopeptidase N (Myeloid Plasma Membrane Glycoprotein CD13 or Alanyl Aminopeptidase or Aminopeptidase M or Microsomal Aminopeptidase or gp150 or CD13 or ANPEP or EC 3.4.11.2) - Product Development Milestones 44
Featured News & Press Releases 44
Apr 19, 2018: Pharmaleads to Present Data on PL37 at BioTrinity 2018 in London 44
Apr 19, 2018: Pharmaleads to Present Data on PL265 at BioTrinity 2018 in London 44
Mar 13, 2018: First subject enrolled in Phase I clinical trial of its non-opioid analgesic STR-324 44
Jan 16, 2018: Eiger BioPharmaceuticals Announces Phase 2 LIBERTY Study in Pulmonary Arterial Hypertension Did Not Meet Primary Endpoint 44
Jan 04, 2018: Eiger BioPharmaceuticals Completes Enrollment of Phase 2 ULTRA Study of Ubenimex in Primary and Secondary Lymphedema Patients 45
Jun 29, 2017: Pharmaleads Reports Positive Phase I SAD Data with its Dual ENKephalinase Inhibitor PL265 for the Treatment of Neuropathic Pain 45
Jun 01, 2017: MolMed provides update on Zafiride Conditional Marketing Authorization application 46
May 17, 2017: Eiger Announces Results Demonstrating Benefit of Ubenimex and Leukotriene B4 (LTB4) Modulation in Experimental Lymphedema 47
May 15, 2017: Eiger BioPharmaceuticals Completes Enrollment of Phase 2 LIBERTY Study of Ubenimex in Pulmonary Arterial Hypertension 47
May 12, 2017: Pharmaleads Reports Positive Ocular Pain Results with PL265, a Novel Dual Enkephalinase Inhibitor, at the ARVO 2017 Annual Meeting 48
May 05, 2017: Pharmaleads to Present PL265 for Ocular Pain Results at the ARVO 2017 Annual Meeting in Baltimore 49
May 04, 2017: Eiger BioPharmaceuticals to Host Key Opinion Leader Event Addressing Need for Novel Mechanisms in the Treatment of Pulmonary Arterial Hypertension (PAH) on May 10th in New York City 49
Jan 03, 2017: Eiger Announces First Patient Dosed in Open-Label Extension of Phase 2 LIBERTY Study of Ubenimex in Pulmonary Arterial Hypertension 50
Dec 23, 2016: The European Medicines Agency has Validated the Submission of Conditional Marketing Authorisation for NGR-hTNF 51
Dec 06, 2016: MolMed files a Conditional Marketing Authorisation in the European Union for NGR-hTNF 51
Appendix 52
Methodology 52
Coverage 52
Secondary Research 52
Primary Research 52
Expert Panel Validation 52
Contact Us 52
Disclaimer 53

List Of Tables

List of Tables
Number of Products under Development by Stage of Development, H1 2018 8
Number of Products under Development by Therapy Areas, H1 2018 9
Number of Products under Development by Indication, H1 2018 11
Number of Products under Development by Companies, H1 2018 12
Products under Development by Companies, H1 2018 13
Number of Products under Investigation by Universities/Institutes, H1 2018 14
Products under Investigation by Universities/Institutes, H1 2018 15
Number of Products by Stage and Mechanism of Actions, H1 2018 16
Number of Products by Stage and Route of Administration, H1 2018 18
Number of Products by Stage and Molecule Type, H1 2018 20
Pipeline by MolMed SpA, H1 2018 21
Pipeline by Nippon Kayaku Co Ltd, H1 2018 21
Pipeline by Pharmaleads SA, H1 2018 22
Dormant Products, H1 2018 41
Dormant Products, H1 2018 (Contd..1), H1 2018 42
Discontinued Products, H1 2018 43

List Of Figures

List of Figures
Number of Products under Development by Stage of Development, H1 2018 8
Number of Products under Development by Therapy Areas, H1 2018 9
Number of Products under Development by Top 10 Indications, H1 2018 10
Number of Products by Stage and Mechanism of Actions, H1 2018 16
Number of Products by Routes of Administration, H1 2018 17
Number of Products by Stage and Routes of Administration, H1 2018 17
Number of Products by Molecule Types, H1 2018 19
Number of Products by Stage and Molecule Types, H1 2018 19

Methionine Aminopeptidase 2 (Initiation Factor 2 Associated 67 kDa Glycoprotein or Peptidase M 2 or eIF 2 Associated p67 Homolog or METAP2 or EC 3.4.11.18) - Pipeline Review, H2 2018

Methionine Aminopeptidase 2 (Initiation Factor 2 Associated 67 kDa Glycoprotein or Peptidase M 2 or eIF 2 Associated p67 Homolog or METAP2 or EC 3.4.11.18) - Pipeline Review, H2 2018Methionine

USD 3500 View Report

Aminopeptidase N - Pipeline Review, H1 2018

Aminopeptidase N (Myeloid Plasma Membrane Glycoprotein CD13 or Alanyl Aminopeptidase or Aminopeptidase M or Microsomal Aminopeptidase or gp150 or CD13 or ANPEP or EC 3.4.11.2) - Pipeline Review, H1 2018According

USD 3500 View Report

Corneal Neovascularization - Pipeline Review, H2 2018

Corneal Neovascularization - Pipeline Review, H2 2018The latest Pharmaceutical and Healthcare disease pipeline guide Corneal Neovascularization - Pipeline Review, H2 2018, provides an overview of the Corneal Neovascularization (Ophthalmology) pipeline

USD 2000 View Report

Kidney Transplant Rejection - Pipeline Review, H2 2018

Kidney Transplant Rejection - Pipeline Review, H2 2018The latest Pharmaceutical and Healthcare disease pipeline guide Kidney Transplant Rejection - Pipeline Review, H2 2018, provides an overview of the Kidney Transplant

USD 2000 View Report

Your are not allow to send sample request

Fill The Form For Sample Request

Note : * Kindly provide us with your company id and get the sample reports at the earliest.

There is no Reviews available